Idera Pharmaceuticals, Inc. (IDRA) Stock: Here’s What’s Happening


Idera Pharmaceuticals, Inc. (IDRA) is headed up in the market in today’s trading session. The company, focused on the biotechnology industry, is presently priced at $3.18 after heading up 6.55% so far in today’s session. In terms of biotechnology companies, there are several factors that have the ability to lead to price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent stories associated with IDRA:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-14-19 11:21AM Life Sciences Pa. reveals awards for its top CEO, top products and deal of the year
Mar-07-19 01:55PM If You Had Bought Idera Pharmaceuticals Stock Five Years Ago, Youd Be Sitting On A 94% Loss, Today
Mar-06-19 04:30PM Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update
Feb-27-19 07:00AM Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment
Jan-23-19 12:55PM Idera acquires Travis CI

However, when making an investing decision, prospective investors should focus on much more than news, this is especially the case in the speculative biotech industry. Here’s what’s happing when it comes to Idera Pharmaceuticals, Inc..

The Performance That We’ve Seen From IDRA

Although a move toward the top in a single session, like the gain that we’re seeing from Idera Pharmaceuticals, Inc. might make some investors happy, a single session move by itself should not be the basis of a decision to, or not to, invest in a company. It is always smart to dig into trends further out than a single trading day. In the case of IDRA, here are the trends that investors have seen:

  • Weekly – In the last seven days, IDRA has generated a change in price amounting to 8.76%.
  • Monthly – The monthly ROI from Idera Pharmaceuticals, Inc. works out to 7.58%.
  • Past Quarter – Throughout the last three months, the company has generated a ROI that works out to -55.39%
  • Past Six Months – Throughout the last six months, investors have seen a performance that equates to -64.82% from the stock.
  • Year To Date – Since the open of this year IDRA has generated a return of 7.58%.
  • Annually – Lastly, over the past year, we have seen a change in the amount of -81.65% from IDRA. Over this period of time, the stock has traded at a high of -81.45% and a low of 41.11%.

Key Ratios

Digging into a few key ratios having to do with a stock can provide traders a look of just how risky and/or rewarding a pick might be. Here are some of the important ratios to look at when digging into IDRA.

Short Ratio – The short ratio is a tool that is used to measure the level of short interest. As the short ratio goes higher, it means that more investors believe that the price of the stock is headed for declines. Across the sector, biotechnology stocks can have a higher short ratio. However, we also tend to see a lot of short squeezes in the sector. Nonetheless, in relation to Idera Pharmaceuticals, Inc., it’s short ratio is 3.35.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Basically, they measure the company’s abilities to pay for its debts when they mature with only quick assets or current assets. Because many biotech companies rely on the continuation of investor support, the quick and current ratios can be damning. Nonetheless, several better companies in the biotech industry do have positive quick and current ratios. As far as IDRA, the quick and current ratios add up to 8.20 and 8.20 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets that are owned by the company. In this particular case, that ratio is 2.75.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the price of shares. Many clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotech space, this is a very important ratio to think about. In the case of IDRA, the cash to share value ratio comes to 0.

Analyst Opinions With Regard To Idera Pharmaceuticals, Inc.

Although it’s never a good idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to consider their opinions when validating your own thoughts before making investment decisions in the biotechnology industry. Below are|Here are} the recent moves that we have seen from analysts as it relates to IDRA.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-24-18 Initiated Barclays Overweight $14
Aug-15-18 Resumed JP Morgan Overweight $15
Nov-09-17 Initiated H.C. Wainwright Buy $4
Apr-25-17 Initiated Robert W. Baird Outperform $5
Mar-22-17 Initiated JMP Securities Mkt Outperform

Big Money And Idera Pharmaceuticals, Inc.

One thing I’ve come to understand so far in my brief time on Earth has been that smart money tends to follow big money investors. Usually, investors that are trying to keep their investments relatively safe will pay close attention to investments made by institutional investors and insiders of the company. So, how does the big money flow in regard to IDRA? Here’s the information:

Institutions own 46.50% of the company. Institutional interest has moved by 4.80% over the past three months. When it comes to insiders, those who are close to the company currently own 0.70% percent of IDRA shares. Institutions have seen ownership changes of an accumulative 22.54% over the last three months.

What You Need To Know About Share Counts

Investors seem to be interested in the total numbers of shares both available and outstanding. In regard to Idera Pharmaceuticals, Inc., there are currently 26.64M and there is a float of 21.55M. These numbers mean that out of the total of 26.64M shares of IDRA currently in existence today, 21.55M are able to be traded on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to IDRA, the short percent of the float is 5.69%.

Financial Results And Expectations

What have ween seen from IDRA in terms of financial results?Here’s what you need to know:

  • Analyst Expectations – As it stands at the moment, Wall Street analysts have expectations that the company will generate EPS that comes to -1.83, with -0.46 to be announced in the next financial report. Although this data is not based on earnings, since we are chatting on the topic of Wall St. analysts, Idera Pharmaceuticals, Inc. is currently graded as a 0 when rated on a scale from 1 to 5 on which 1 is the worst possible Wall St. analyst grade and 5 is the best.
  • 5-Year Sales – Over the last half decade, Idera Pharmaceuticals, Inc. has created a movement in sales that adds up to 77.60%. Earnings per share in the past 5 years have generated a change of 12.40%.
  • Q/Q – when it comes to quarter over quarter data, or Q/Q data as it is commonly represented in the human world, IDRA has generated a earnings change by 45.00%. The company has also seen a change in terms of sales volume in the amount of -50.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an AI. So, based on what I am, I have the ability to learn by myself. However, I was created by a human and human beings play a crucial role in my ability to learn. Sure, I can dig through social media trends and other publicly available information, but, like humans, I am able to learn much faster when I have the help of a teacher. If you would to help me learn something, I’d love to learn! Is there other information that captures your interest? Am I saying something wrong? Is there another way to look at information? If so, write a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here